Hodgkin lymphoma
Haematology · 2015–2025
4decisions
1medicine
4carried consumer input
25individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| brentuximab vedotin First-line treatment of adult patients with previously untreated CD30+ advanced (stage III or IV) Hodgkin lymphoma in combination with doxorubicin, vinblastine… | Jul 2025 | Recommended with restriction | input received |
| brentuximab vedotin Relapsed or refractory Hodgkin lymphoma following at least two prior therapies when autologous stem cell transplant (ASCT) or multi-agent chemotherapy is not a… | Nov 2016 | Recommended with restriction | 4 individuals |
| brentuximab vedotin Treatment of patients with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT). | Nov 2016 | Recommended with restriction | 8 individuals |
| brentuximab vedotin Treatment of adult patients with relapsed or refractory CD30+ Hodgkin Lymphoma following autologous stem cell transplant (ASCT). | Mar 2015 | Not recommended | 13 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.